Skip to main content

Table 4 Comparison of the percentages of B cell subsets between untreated MS patients, IFN-β-treated MS patients, and healthy controls

From: Long-term use of interferon-β in multiple sclerosis increases Vδ1Vδ2Vγ9 γδ T cells that are associated with a better outcome

 

Untreated MS (n = 35)

MS w/ IFN-β (n = 21)

HCs (n = 44)

p value (K-W test)

padj value

Untreated MS vs. HCs

MS w/ IFN-β vs. HCs

Untreated MS vs. MS w/ IFN-β

Naïve (CD27IgD+)

46.3 (27.9–56.8)

48.9 (37.7–58.9)

51.8 (41.4–60.6)

NS

Memory (CD27+)

14.8 (10.3–27.0)

9.84 (6.89–15.2)

22.7 (16.9–29.9)

< 0.001

NS

< 0.001

0.009

 CS+ memory (CD27+IgD)

12.4 (9.27–24.8)

7.97 (6.10–14.0)

18.8 (14.4–25.2)

< 0.001

NS

< 0.001

0.006

 CS memory (CD27+IgD+)

1.91 (0.83–2.68)

0.99 (0.85–1.67)

3.49 (2.49–4.67)

< 0.001

NS (0.058)

< 0.001

NS

Plasmablasts (CD38highCD20)

0.31 (0.14–0.65)

0.32 (0.25–0.53)

0.37 (0.24–0.67)

NS

Transitional (CD24highCD38high)

3.16 (1.75–5.93)

5.90 (1.92–7.66)

3.14 (2.32–4.45)

NS

  1. Values are the median (IQR). Percentages of each population in total B cells are shown
  2. p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then padj values were calculated using multivariate linear regression analyses adjusted for age and sex
  3. CS+ class-switched, CS non-class-switched, HCs healthy controls, IFN-β interferon-β, IQR interquartile ranges, K-W Kruskal-Wallis, MS multiple sclerosis, NS not significant, w/ with